Activation of ERK1/2 Causes Pazopanib Resistance via Downregulation of DUSP6 in Synovial Sarcoma Cells

Synovial sarcoma (SS) is a rare high-grade malignant mesenchymal tumour with a relatively poor prognosis despite intensive multimodal therapy. Although pazopanib, a multi-kinase inhibitor, is often used for advanced SS, most cases eventually become resistant to pazopanib. In the present study, we in...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokoyama, Nobuhiko, Matsunobu, Tomoya, Matsumoto, Yoshihiro, Fukushi, Jun-ichi, Endo, Makoto, Hatano, Mihoko, Nabeshima, Akira, Fukushima, Suguru, Okada, Seiji, Iwamoto, Yukihide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368598/
https://www.ncbi.nlm.nih.gov/pubmed/28350009
http://dx.doi.org/10.1038/srep45332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368598/
https://www.ncbi.nlm.nih.gov/pubmed/28350009
http://dx.doi.org/10.1038/srep45332

Ejemplares similares